FDA says more data needed on how well 3rd doses work in this age group, creating uncertainty over when the shots will be okayed for young children

Researchers find women reported more mild reactions such as headaches, pain at injection site after getting Pfizer shot; reasons unclear

Examining thousands of women for incidence of preterm births, hospitalizations, birth defects and mortality, research says no difference between vaccinated and unvaccinated

Chief Executive Albert Bourla says 2021 was a 'watershed year' for drugmaker, with its efforts during the pandemic 'fundamentally changed our company forever'

'We need collectively to be rethinking what is the goal of vaccination,' doctor says, as shots prove effective at saving lives but not in preventing spread of new variants

Regulators urging drugmaker to apply for emergency authorization of 2-dose regimen of shot for kids aged 6 months to 5 years old while awaiting data on 3-dose course

CEO Albert Bourla has said pharmaceutical giant could be ready to file for regulatory approval of tweaked dose by March

Ministry says 2nd booster also doubles protection against infection during current wave; officials mull scrapping Green Pass restrictions

Albert Bourla says US-based pharma firm is aiming to produce annual shot to cover all COVID variants; accuses anti-vaxxers of causing millions of deaths by spreading misinformation

Research dashes hopes that new boosters will deliver Omicron-proof protection, but they may still help the elderly and at-risk by reducing chances of serous illness